Nexlizet is an anti-cholesterol drug owned by Esperion Theraps Inc. This medication contains Bempedoic Acid and Ezetimibe as its active ingredients. Nexlizet first came to the market on 26 February 2020.
Nexlizet has a total of 10 drug patents, 5 of which have already expired. The potential release date for Nexlizet generics, however, is not until after 19 June 2040. This is due to patents like US11760714, titled 'Methods of making bempedoic acid and compositions of the same', which expires on 19 June, 2040.
Nexlizet is primarily used as an adjunct to diet and maximally tolerated statin therapy for inhibiting cholesterol synthesis and lowering LDL-C in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease. This is achieved through the combined effect of 180 mg of Bempedoic Acid and 10 mg of Ezetimibe.
Nexlizet is protected by 10 patents, but only 5 are currently active. The patent with the latest expiration date is US11760714, which will expire on 19 June, 2040. Thus, the potential release date for Nexlizet generic is after that date. Below are the details of the patents: